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Abstract: Trade liberalisation and changes in the Intellectual Property Rights 
(IPR) have fashioned new dynamics in the pharmaceutical industry across  
the globe. Firms are forced to bring changes to their research, innovation, 
technology and marketing practices by a reconfiguration of their competencies 
and resources. The most common strategic concern that Trade Related Aspects 
of Intellectual Property Rights (TRIPs) has raised for Indian firms is the 
perceived need for R&D and technological strength. For firms that have given 
little attention to research and innovation in the past, this transition is very 
difficult. Indian firms have responded to these changes in novel and complex 
ways. Employing firm-level case studies, this paper examines the contemporary 
strategic approaches adopted by Indian leaders for integrating new knowledge 
and capabilities in order to develop innovation competencies for tomorrow. 
Using empirical evidence from firm-level investigations, this paper shows 
how Indian firms are evolving from reverse engineering outfits catering to 
domestic market to technologically advanced and sophisticated organisations 
capable of catering to diverse markets. 
Keywords: knowledge; innovation competencies; Indian pharmaceutical  
firms; strategies. 
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the study of policy, knowledge and market influences in shaping up  
firm-level technological trajectories and changing innovation dynamics. In her 
professional work spanning research, industry and government experience,  
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This paper is based on a recently completed and unpublished PhD thesis titled 
‘The dynamics of technology innovation in The Indian Pharmaceutical 
Industry: firm strategy and policy interactions’ (Faculty of Technology, 
Development Policy and Practice, The Open University, Milton Keynes). 
The paper was first presented at The 3rd Asialics International Conference 
2006, in Shanghai, China, 16–19 April 2006. 
 
1 Introduction 
How and why do firms adapt and succeed in times of rapid change? Theoretically, there 
are a number of mechanisms through which firms can transform themselves in response 
to environmental challenges. Researchers have looked from very different angles at  
how environmental factors such as policy, knowledge and market dynamics can affect 
firm-level strategies. Schumpeter (1947), with his ‘gales of creative destruction’, gave a 
vivid description of the dynamism of innovation and its effects on industrial and world 
economy. Many authors further elaborated on this theory, notably Rosenberg (1969), 
Nelson and Winter (1977) and Freeman and Perez (1988). A very different and dominant 
paradigm that emerged in strategy during the 1980s was the competitive forces approach 
developed by Porter (1990), wherein he argued that industry structure strongly influences 
the competitive rules of the game as well as the strategies. 
Another distinct class of approaches that link firm-specific capabilities and assets 
with its strategies, often referred to as the resource-based perspective, have their roots  
in the much older work of Penrose (1959) and Selznick (1957). Recently there has been  
a resurgence of interest in the role of firm’s resources and capabilities as the foundation 
for firm strategy (Teece et al., 1997). Modern literature on innovation management has 
identified knowledge as a critical resource, and research and innovation as firms’ core 
competencies (Pavitt, 1990; Leonard-Barton, 1992; Malerba and Orsenigo, 2001). Keller 
(2004), in a recent review of the resource-based model of the firm, noted that researchers 
are increasingly focusing on the intangible resources of diverse knowledge bases and 
capabilities which differentiate firms and lead to superior performance. From this 
perspective, technology development ought to be considered as a knowledge-led process 
and knowledge-management as a strategic necessity for firms.  
   
 
   
   
 
   
   
 
   
    Strategic integration of knowledge in Indian pharmaceutical firms 29    
 
 
    
 
 
   
   
 
   
   
 
   
       
 
Evolutionary economists emphasise the cumulative and dependent nature of technical 
and organisational change within firms. The particularities of the way different firms 
incorporate new technology and new processes need to be understood in the context of 
their previous trajectories and their capacity to absorb new knowledge (Cohen and 
Levinthal, 1990). 
A number of studies have recently looked at the impact of knowledge-related policy 
changes coupled with enhanced knowledge levels on the social, economic and 
technological development of developing countries. Lanjouw (1997), Kumar (2002) and 
Correa (2000) have studied the impact of stringent patent regimes on the social, 
technological and economic development of India. Halemane and Dongen (2003) 
investigated innovation management in the Indian pharmaceutical industry as a response 
to environmental changes based on the theories of strategic groups from industrial 
economics. But most of these studies have focused on the relationships between the 
actions that firms have taken and the outcomes (success and failures) and have paid less 
attention to the strategies underlying those actions. 
In parallel to the academic literature, firms in developed and developing countries 
have increasingly seen knowledge capabilities and knowledge management as key 
resources. In part, this is driven by new policy developments in intellectual property 
protection and Trade Related Aspects of Intellectual Property Rights (TRIPs). 
Picking up from where others have left off, this paper analyses the technology 
development, innovation and wealth creation approaches (strategies) being adopted by 
Indian pharmaceutical firms in the wake of a rapidly changing technology and policy 
environment. The terms ‘innovation’ and ‘knowledge’ in this paper are not restricted to 
technology alone, but encompass other business and management processes as well. In 
practice also, the R&D function in business firms has shifted focus to the strategic 
integration of the R&D effort with the overall business goal (Madanmohan and Krishnan, 
2003; Sakakibara and Dodgson, 2003; Bower and Sulej, 2005). These shifts reflect the 
increasing complexity and maturity in which companies are tackling the management  
of their technology, products and markets. The paper analyses the key elements of  
the strategic trajectories of leading Indian pharmaceutical firms which have been 
demonstrably successful in the domestic as well as western markets in the past and  
are currently aggressively expanding their activities to build innovation competencies  
for tomorrow. 
Structure of the paper 
This research coincides with a period of rapid restructuring in the regulatory framework, 
patent laws and market dynamics across the globe. The principal objective of this  
paper is to look at the effects of TRIPs on the research and innovation strategies of  
Indian pharmaceutical firms. Section 2 presents the research context and the theoretical 
framework which guides the research. This section also describes the methodology of the 
study and rationale behind using such a research design. In order to understand Indian 
firms’ response, it is crucial to look at them in the context of key historical factors. 
Section 3, as historical background, explains capacities and capabilities created within the 
Indian pharmaceutical industry in the process patent regime and shows how changes in 
policy regimes have influenced technological choices and trajectories of Indian firms 
over time. Section 4 looks at how firms are strategising for innovation-based post-TRIPs 
competition. Section 5, while discussing the key observations of this study, maps the 
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transformation of Indian firms as they move from process engineering (working at the 
lower end) to drug discovery (the higher end of pharmaceutical value chain). The paper 
concludes with a few final thoughts and a summary of firm-level strategies in Section 6.  
2 Context, framework and methodology 
2.1 The research context 
It is well established in the literature (Kumar, 2002; Watal, 2000; Rasiah, 2002) that the 
technological advance achieved by the Indian pharmaceutical industry owes much to the 
1970 Patents Act. In the 1970s, India introduced complex laws and policies to regulate 
the pharmaceutical industry, to counteract monopoly abuses by multinationals and to 
promote local industry. The reforms included changes to foreign exchange regulations, 
price controls, industrial licensing and most important of all, the non-recognition of 
pharmaceutical product patents that legalised reverse engineering of patented molecules. 
The reforms contributed to many tangible benefits such as the creation of manufacturing 
capacities, lower drug prices, and availability of modern drugs to the masses.  
From an Indian perspective, the lack of Intellectual Property Rights (IPR) laid the 
foundation for a strong domestic industry. The recent signing of the TRIPs agreement, 
however, reverses the patent law followed since the 1970s. The firms that have developed 
knowledge and capabilities in reverse engineering-based R&D in the past are required to 
reorient themselves for R&D-based innovation to survive and compete in a regulated and 
open market. This has serious implications for the Indian pharmaceutical firms. Apart 
from upsetting their balance sheets and profits earned through exports of cheaper versions 
of patented drugs, access to new knowledge and technology is envisaged to be even  
more difficult in the stricter patent regime. Given this context, this paper examines the 
organisational processes employed to manage knowledge and innovation by Indian firms 
involved in a complex change process today.  
2.2 Theoretical framework 
The theoretical framework for this research is based upon the theories of co-evolution  
of policy and technology, and dynamic capabilities of firms and strategic knowledge 
management.  
2.2.1 Policy analysis for research and innovation  
This research proposes a novel application of the ‘content, context and process’ 
framework for policy analysis in the pharmaceutical sector. The research argues that 
much health policy wrongly focuses attention on the content of reform, and neglects  
the actors involved in policy reform (at the international, national, sub-national levels), 
the processes contingent on developing and implementing change, and the context within 
which policy is developed. Exclusive focus on policy content can divert attention from 
understanding the processes which explain why desired policy outcomes fail to emerge, 
for example, failure of strong IPRs in facilitating knowledge and technology transfer 
from developed to developing countries in the past. Focusing on the role of ‘firms’ in 
‘making’ policy work, this research examines how policy analysis can be used not only  
to analyse the policy process, but also to better think about research, innovation and 
business strategies at the firm level.  
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2.2.2 Strategic alliances for knowledge integration 
The fundamental question in the field of strategic management of R&D is how firms 
achieve and sustain competitive advantage in rapidly changing scenarios. Teece et al. 
(1997) confronted this question by developing the ‘dynamic capabilities’ approach. 
Stemming from fundamental firm-level efficiency advantage, the approach emphasises 
firm-specific capabilities and assets. The capabilities here do not represent technological 
capabilities alone but also management capabilities and difficult-to-imitate combinations 
of organisational, functional and technological skills. The dynamic capabilities 
framework directly addresses a firm’s ability to strategically integrate, build and 
reconfigure internal and external competencies to address rapidly changing environments. 
Chiesa and Toletti (2004), in their recent study of the biotechnology sector, have also 
highlighted the role of strategic alliances in the development of R&D capability, the rate 
and quality of innovation, knowledge transfer, and organisational learning.  
A review of firm-level case studies in other developing countries like China, Korea 
and Taiwan (Kim, 1997; Lee, 2000) suggests that the creative destruction of existing 
competencies and adoption of new practices is not an easy task and definitely not a  
one-step-straightforward process. The move has to be gradual and needs to be addressed 
strategically rather than purely technically. Within this framework, the present paper 
analyses the gradual reorientation of the Indian firms towards innovation-based R&D. 
Focusing at the firm level, the paper looks at research and innovation strategies that are 
being devised by the top Indian firms to attain leadership in the domestic market and 
carve a niche for themselves in the international market in the post-TRIPs regime.  
2.3 Research methodology 
Drug discovery and implementation of new product development processes are both 
contemporary phenomena as far as the Indian pharmaceutical industry is concerned.  
Both exert pressure on firms to strategically reconfigure their research and market 
activities. The success of firms operating under these pressures is determined by their 
propensity to innovate and commercialise innovations within the given space, time and 
opportunities. The data needed to investigate these issues require detailed information  
on the firm(s)’ R&D base, technical capabilities and its own technology policy and 
strategy. In this study we also felt it essential to interact with the firms and conduct  
in-depth studies in order to understand how firms are dealing with the changing policy, 
knowledge and markets emerging in the post-2005 scenario. A multiple-case design was 
used and cases were chosen on the basis of degree of innovativeness and strategies to 
transform themselves. 
The field work was conducted in two phases: preliminary and main investigations, the 
latter of which was to have detailed discussions on the issues identified in the preliminary 
phase and to provide an opportunity for us to make amendments. The preliminary phase 
mapped out major actors (individuals and institutions) and critical issues surrounding our 
research question through eight to ten pilot interviews which helped the final selection of 
cases and the research design for in-depth investigation in the second phase. A company 
dossier was made for each, combining the results of primary and secondary sources, 
including the analysis, observations and critique contributed by the researcher. The 
dossiers proved valuable in spotting commonalities and differences in the strategic 
content of the main research themes at the firm level and their overall approach to 
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innovation in the post-TRIPs regime. The multiple-case study method allowed replication 
logic, with each study confirming or disconfirming inferences from previous ones, 
thereby permitting induction of more reliable strategies. 
Special use of existing literature was made to analyse the causes and effects of  
the legal and policy changes of the last five decades and to map the evolution of the  
Indian pharmaceutical industry in the pre-TRIPs era. Literature on the evolution of  
the Indian pharmaceutical industry was sourced from the annual reports of the Ministry 
of Science and Technology, the Ministry of Commerce and Industry, Parliamentary 
reports and reports published by individual organisations and authors (NCAER, 1984; 
Watal, 2000; Lall, 1984; Zaveri, 2002). In addition, industry journals trade journals, and 
industry associations’ publications were also referred to. 
3 History of Indian pharmaceutical industry 
The story of the growth of the Indian pharmaceutical industry is a fascinating one. With 
approximately 5877 companies, the Indian pharmaceutical industry is currently one of  
the most fragmented in the world and provides an excellent case of Indian industry as  
a whole. 
Before Independence, despite modest efforts on the part of the colonial government  
to spur local production, India was fully dependent on other nations for vital drug 
supplies. The independent government, in 1947, emphasised rapid industrialisation and 
invested heavily in pharmaceuticals (amongst other industries), yet did not discourage 
foreign companies from competing in India. As a result, even well after Independence, 
foreign-held patents ruled the Indian pharmaceutical industry and drug prices in India 
were among the highest in the world (Kefauver Senate Committee Report, 1962). The 
situation today is just the opposite. One of the important successes of economic and 
social development has been to make life-saving drugs available at affordable prices. 
This success is largely attributed to a combination of policy-led technological advances 
consciously followed since the late 1960s and the specific objective of providing 
affordable drugs for the masses.  
The co-evolution of policy and technology that took place post-independence in India 
is clustered under four major policy time frames and is discussed in the sub-sections  
to follow. 
3.1 Post-independence technology efforts (early years) 
The government took its first concrete steps towards self-reliance in pharmaceuticals  
and healthcare in 1954 with the establishment of Hindustan Antibiotics Limited (HAL), 
followed by Indian Drugs and Pharmaceutical Ltd. (IDPL) in 1961. These two enterprises 
played an important role not only in starting domestic production of key bulk drugs  
but also in diffusing substantial spillovers in terms of technical know-how, technology 
transfer and the technology innovation process/system itself, and more importantly  
in generating entrepreneurs. One of the important observations of the fieldwork 
undertaken for this study has been that founders of many successful enterprises  
worked with these organisations initially, including the founder of the immensely 
successful Dr. Reddy’s Laboratories. 
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The modest growth rates achieved jointly by the public and private initiatives, though 
useful and timely, were not enough to jumpstart local production. The pharmaceutical 
industry policies for the 20 years after independence continued to emphasise national 
health and self-reliance rather than indigenous production and allowed Multinational 
Corporations (MNCs) to exploit the Indian market. By 1970, the industry had a huge 
MNC presence, most of which maintained minimal physical operations in India (Smith, 
2000). Thus, MNCs had the benefit of operating in a free market with exclusive 
privileges for 16 years (under the Patents and Design Act, 1911) without having to 
contribute anything to the local industry. The combination of these provisions had a 
negative impact on the industry. 
3.2 Post-1970 technological progress 
Before 1970, patent protection served to encourage foreign inventors and foreign R&D. 
MNCs patented their inventions in India, but did not produce locally, using the patents  
to establish a protected foreign market in the country (Justice Ayyangar, 1959, p.12).  
This not only denied the spillovers of technologies developed by MNCs to the local 
innovation system, but also did not help develop local technological capabilities. The 
need for a system that encouraged technology acquisition, transfer, development, 
diffusion and incremental innovation was obvious. Patent Law was used as a tool  
to establish this system in India. It was The Indian Patents Act, 1970, that laid the 
foundation of the local industry.  
In the 1970s, India introduced complex laws and policies to regulate the 
pharmaceutical industry, to counteract monopoly abuses by multinationals and to 
promote local industry. The reforms included changes to foreign exchange regulations, 
price controls, industrial licensing and, most important of all, the non-recognition of 
pharmaceutical product patents. The Patents Act, 1970, which came into effect in 1972, 
represented a significant change in the legal and technological regime and had an 
enormous impact on the technological evolution of the pharmaceutical industry in India. 
It started the era of reverse engineering, where firms developed new products by simply 
changing a few steps in their production processes. Beginning in the late 1970s and  
early 1980s, legal reverse engineering made new technologies and new drugs available 
easily and at an affordable price. These reforms not only enabled the emergence of a 
competitive domestic industry but also set the foundation for generic drug production. 
3.3 Technological progress in the liberalised economy 
Before liberalisation began, protection of domestic production and local technological 
efforts enabled India to build up a diverse and fairly sophisticated base in the 
pharmaceutical sector. However, technological backwardness and lack of genuinely 
innovative products were evident. The fresh lease of reforms in 1991 (liberalisation) set 
the pace for technological advancement. Once the Indian market was opened up to 
foreign firms and the import of goods, demand for improved manufacturing processes 
and new products drove the need for new technology and innovative products at par with 
international products.  
Indian firms responded to liberalisation in many different ways. Much new 
technology was imported, but our case studies show that particular firms started investing 
more in in-house R&D as a move to build a proprietary technological base. Some firms 
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like Ranbaxy, Dr. Reddy’s and Sun increasingly started focusing on Novel Drug Delivery 
Systems (NDDS), thereby adding their own value to the existing products. “There were 
even more successful attempts to produce products better tailored than MNC drugs for 
the Indian market” (Smith, 2000, p.14). 
Pharmaceutical firms like Cipla, Alembic, Cadila, Zydus and Lupin improved  
their manufacturing efficiency and established large production facilities. Some firms like 
Sun, Torrent, Dabur, Cadila, Ranbaxy and Wockhardt restructured and shifted their 
technology focus, product basket and market focus. Special emphasis was given to 
strengthening marketing and distribution networks after liberalisation. Indian firms 
increased their in-house R&D investments and implemented new approaches to 
drug/product development. Most technological changes during this era were driven by 
competition via liberalisation. However, the changes were not entirely due to this reason. 
Some ambitious and visionary firms started taking technological initiatives even before 
liberalisation. Nonetheless, liberalisation did set the pace.  
The firms studied have restructured and changed in some combination of the above 
responses and the changes are cumulative. Even without strong patent protection, Indian 
firms matured during the 1990s. In particular, large firms have grown less reliant on 
reverse engineering and have developed capabilities for NDDS. Our evidence indicates 
that the combined effect of policy and market shifts has facilitated a ‘research tradition’ 
in the Indian pharmaceutical firms to a very large extent. 
3.4 The new patent regime (TRIPs) and challenges ahead 
The growth of the Indian pharmaceutical industry over the last four decades owes a lot  
to the 1970 Patent Act, which allowed the domestic manufacturing and marketing  
of patented products without a licence. During the process patent regime, Indian  
firms developed competence in applied research for developing production-process 
technologies, particularly for synthetic bulk drugs. However, the drugs and 
pharmaceutical industry in India today faces many challenges stemming from 
liberalisation of the Indian economy, globalisation of the world economy and new 
obligations undertaken by India under TRIPs. The 1970 Patents Act that facilitated the 
extraordinary growth of the domestic industry has been totally reversed with the signing 
of the TRIPs agreement in 1991. TRIPs marked the turning point of India’s policy regime 
towards the world.  
At the national level, these challenges require a change in emphasis in the current 
pharmaceutical policy and the need for new initiatives beyond those enumerated in  
the Drug Policy 1985, and modified in 1994, so that policy inputs are directed more 
towards promoting accelerated growth of the pharmaceutical industry and towards 
making it more internationally competitive. The Drug Policy 2002 has been framed 
against this backdrop. 
Similarly, changes are required at the firm level, with more emphasis and focus on 
technology and innovation. In the process patent regime, the emphasis has been on 
reverse engineering and production of generics, and the R&D focus of firms during this 
era clearly reflects this. Firms need to improve their R&D efforts to produce quality 
drugs, whether generics or new, not only to compete with MNCs in the liberalised market 
but also to enhance exports to the developed world. A shift to a product patent regime 
would demand capability development for indigenous research to enable the industry to 
achieve sustainable growth. The large players have already started upgrading their R&D 
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capabilities and various approaches are being adopted to cut time and cost factors and add 
quality and innovation in drug development, which are discussed in the next section. 
Interestingly, not all firms are pursuing identical strategies. The following section 
discusses firm R&D strategy in more detail. 
4 Firm strategies in the post-TRIPs regime 
As is evident from the discussion in the previous sections, Indian firms developed  
their knowledge and capabilities in reverse engineering-based R&D in the pre-TRIPs era. 
The new patent regime that does not allow reverse engineering of known molecules, 
together with the pressure exerted by liberalisation and globalisation, is forcing firms  
to transform their R&D activities and realign their competencies. Firms like Ranbaxy,  
Dr. Reddy’s, Dabur, Sun, Wockhardt, and Torrent are seriously pursuing new drug 
discovery programmes now. This study suggests that these are the firms, generally, that 
have invested more in the R content of R&D and have gradually moved away from 
reverse engineering. Other firms like Cipla, Lupin, Cadila and NPIL have invested more 
in the D content and have strengthened their infrastructure and financial position through 
process efficiencies, economies of scale and large product baskets rather than research. 
These firms are of the opinion that technology needs to be fostered gradually and hence 
they take a slightly different route to drug discovery. Within these two very broad 
categories there is further differentiation. 
Firms have different views on how to ensure success in this new environment  
and hence have different strategies. As evolutionary economists suggest, competencies 
created in the past vary from one firm to another and each firm has therefore devised a 
different strategy for itself. Nonetheless, R&D does seem to be judged as essential in the 
long term by all firms. State-of-the-art R&D facilities, equipped with sophisticated 
instruments, equipment and skills, are considered an absolutely essential part of corporate 
strategy and, accordingly, investments are being made (company interviews and visits to 
research parks).  
Sceptics, however, assert that Indian firms are not large enough to discover and 
develop their own drugs. Also, Indian firms lack the experience of MNCs that have spent 
the better part of the 20th century honing their R&D skills (Smith, 2000). In spite of all 
these odds, the firms have ambitious plans to launch their own New Chemical Entities 
(NCEs) and new drugs and have charted R&D strategies to build and fuel their drug 
discovery pipeline, albeit with a different time frame (short, medium and long). These 
strategies are discussed firm by firm. 
4.1 Ranbaxy Laboratories Limited 
Ranbaxy positions itself as aspiring to become a research-based international 
pharmaceutical company. In pursuit of such an objective and in the changing 
environment, Ranbaxy has responded by taking three initiatives: new drug discovery, 
domestic strengthening, and globalisation. Initially, Ranbaxy catered to the domestic 
market by manufacturing branded generics, pharmaceuticals, bulk actives and 
intermediates and spent little on R&D. In the last few years, however, the company has 
taken major initiatives and made investments to create infrastructure and state-of-the-art 
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dedicated R&D facilities at its R&D centre and to enhance its capabilities in the area of 
New Drug Discovery Research (NDDR). According to the President of R&D, Ranbaxy’s 
overall R&D spending of around 5% of sales continues to be the highest, in value terms, 
in the Indian pharmaceutical sector. 
The company’s foray into Novel Drug Delivery Systems (NDDS) has paid rich 
dividends in the form of unique proprietary-control release-platform technologies. The 
development of a unique once-a-day formulation of Ciprofloxacin, which has been 
licensed to Bayer AG, originator of this molecule, has been a breakthrough success for 
the company (Annual Report 2002). Driven by therapeutic choice, the company’s NDDR 
activity has made significant strides in areas like anti-infectives, respiratory, and urology. 
Responding to the status of NCEs, the R&D President gave information about the five 
NCEs in its pipeline at various stages of development (Table 1). 
Table 1 Ranbaxy’s pipeline of new chemical entities 
Compound Therapeutic area Development status 
RBx 6198 Urology Discovery phase 
RBx 8444 Urology Discovery Phase 
RBx 2258 Urology Phase II (licensed to Schwarz Pharma) 
RBx 7796 Respiratory Phase II, IND* Filed 
RBx 7644 Anti-bacterial Phase II, IND* Filed 
Note: * Investigational New Drug 
Source: Company Interview and Annual Report 2002–2003 
The company has decided to conduct clinical trials by itself in India, unlike Dr. Reddy’s, 
who has opted to license out its molecules to MNCs for advanced clinical trials. The 
strategy is expected to save money in the short term and offer investors a large share of 
revenues from the new drugs, but on the other side it may also deny timely access to 
lucrative western markets.  
Unlike NDDR, NDDS products are launched with strategic tie-ups with other  
leading pharmaceutical companies employing the company’s proprietary technologies. 
Pharmaceutical research continues to strengthen the company’s international presence 
through its focus on technology-intensive, difficult-to-make ‘niche’ products. In 
biotechnology, the current focus is to identify new biological targets (genomics, 
proteomics and bioinformatics) and develop DNA-based biopharmaceuticals and 
vaccines. In the phytomedicines (herbal drug research), the strategic focus is to develop 
high-quality nutraceuticals and ethical products and subsequently move into isolation and 
characterisation of active principals, either as NCEs or as potential lead molecules for 
drug discovery. According to the President of R&D, Dr. Khanna, “while most of the 
products in these areas will be developed in-house, the company is evaluating strategic 
tie-ups with other partners to speed up the licensing and development process”. 
In line with its strategy and focus, Ranbaxy is seeking licensing for NCEs at 
advanced preclinical stages or in early clinical phase trials from international companies 
for further development. Overall, this strategy reflects the company’s intent in moving up 
the value chain and in becoming a research-based company. 
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4.2 Dr. Reddy’s Laboratories (DRL) 
Unlike Ranbaxy, which initially started with reverse-engineered products and gradually 
moved up the high-value end, Dr. Reddy’s Laboratories (DRL) opted for a much riskier 
path (new drug discovery), even during its formative years. DRL was the first Indian 
pharmaceutical company to conduct research and begin a drug discovery programme as 
early as 1993 focused on the speedy translation of scientific discoveries into innovative 
products. Drug discovery efforts at DRL focus on early phase discovery and preclinical 
studies of newly synthesised compounds for the treatment of cancer, diabetes, 
dyslipidemia, inflammation and infections. DRL’s current R&D investment at 8% of its 
sales turnover continues to be the highest among the Indian pharmaceutical firms. DRL is 
further increasing its investment in drug discovery and research activities to about 10% of 
the total revenue, a sharp jump from 8% in 2002–2003 (company interview). 
Having identified bio-generics as a significant market area, the company’s strategy  
to enter this market is to have a portfolio of bio-generics in key therapeutic segments  
by leveraging core competencies and focusing on efficiencies along the value chain  
(from development to marketing). According to company sources, initially the 
technology platforms will be utilised to develop capabilities in manufacturing products 
that are already in the world markets, but the ultimate aim is to build up capabilities in 
basic research in biotechnology. The company has a pipeline comprising several 
recombinant proteins in various phases of development for the treatment of cancer, 
diabetes and cardiovascular diseases (Table 2). 
Table 2 Dr. Reddy’s R&D pipeline 
Compound Therapeutic area Development status 
DRF 2593 Diabetes Phase II (licensed to Novo Nordisk) 
DRF 2725 Diabetes and dyslipidemia Phase III (licensed to Novo Nordisk) 
DRF 4158 Metabolic disorders Preclinical done (licensed to Novartis) 
DRF 4832 Metabolic disorders Late preclinical 
DRF 1042 Cancer Phase I completed 
DRF 1644 Cancer Preclinical completed 
DRF 11057 Bacterial infections Preclinical 
DRF 10945 Metabolic disorders/dyslipidemia Preclinical 
Source: Annual Report 2002–2003 and company interview 
Review of the company literature and subsequent interviews suggest that in initially 
focusing on bulk actives (APIs), DRL in the past has used innovation in process 
development and finished dosage to build a profitable and strong business. In 1992 DRL 
started building up its base for the US generics business (Annual Report 2003). But the 
ultimate pharmaceutical challenge – drug discovery research – is being pursued 
intensively to compete in the post-2005 era. So far, DRL has out-licensed three molecules 
– DRF 2725, DRF 2593 in diabetes and DRF 4158 in cancer – to MNCs for development. 
The key strategy to move up the value chain incrementally and manage risks is to  
out-license new molecules to larger pharmaceuticals with resources to take it to the 
market faster. According to the Vice President–Formulations, “this strategic integrated 
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discovery approach is envisaged to meld talent and skills throughout the organisation. 
DRL’s global presence gives the advantage of providing a cost-effective combination of 
critical skills and scale”.  
4.3 Chemical industrial and pharmaceutical laboratories (Cipla) 
Unlike DRL, which entered the market in the mid-1980s with a research focus, Cipla, one 
of the oldest firms (1935), is better known for its reverse-engineering skills. With its 
reverse-engineering strengths facilitated by the Patents Act of 1970, Cipla has made rapid 
progress during the last three decades. Both Dr. Reddy’s and Cipla command a leadership 
position in the domestic market today, albeit with different research strategy strokes.  
Despite the risk of being termed a ‘patent-buster’, Cipla opted for an aggressive 
product development (reverse-engineered) strategy that catapulted it to the top  
league. According to Dr. Hamied, the Chairman and Managing Director of Cipla,  
much of Cipla’s progress is attributed to the company’s strategy and focus on “from 
inception-to-R&D-to-commercialisation and its thrust in making available the very latest 
in modern drugs and advanced delivery systems in a wide range of areas”.  
In many therapeutic categories, such as anti-asthmatics, Cipla offers the widest range 
of possible products. Focusing on process research, Cipla has made substantial progress 
in NDDS and chiral synthesis. Cipla has already developed its first chirally resolved 
molecule, salbutamol, which is an anti-asthma drug. Two of Cipla’s anti-asthmatic 
devices, namely Rotahaler and Zerostat spacer, are patented internationally. The 
company commits significant resources to R&D, which currently is close to 5% of the 
company turnover and is expected to go up (company interview). The R&D work focuses 
on New Improved Chemical Entities (NICE), NDDS and development of patent-free 
processes for known molecules.  
Cipla has a strong pipeline of products and is expected to come out with innovative 
drugs through NDDS and chiral synthesis. Given the public knowledge that Cipla is 
working on improved chemical entities and drug delivery systems, the research pipeline 
of Cipla could be moving on a similar trajectory to Ranbaxy’s. Discussions with the 
company’s Director suggested that it is possible for Cipla to get into joint development 
partnerships with present patent holders of blockbuster molecules to develop improved 
versions by using chiral chemistry.  
Cipla’s top management strongly believes that the key to success in the current 
environment is not basic research but technological innovation. Consequently, Cipla is 
aiming for continuous innovation and complements this by achieving operational and 
marketing excellence. The company has consistently come out with modern drugs that 
multinationals introduce, far more cheaply in the domestic market. The strategy has been 
effective in a price-sensitive market. 
4.4 Nicholas Piramal India Limited (NPIL) 
Quite unlike Ranbaxy, DRL and Cipla, which had focused on pharmaceutical interests, 
Piramal Enterprises was initially in the textiles business. Visualising the opportunities  
in the fast-growing pharmaceutical sector, the Piramal group acquired Nicholas 
Laboratories, a formulations company, from Sara Lee in 1988. After its first acquisition 
in 1988, in the last 15 years NPIL grew to its leadership position through a series of 
acquisitions, mergers and alliances.  
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According to Dr. Sikka, the Senior President, “NPIL aims to be an integrated 
pharmaceutical company with a commitment to discovery, development, manufacture 
and marketing of indigenous pharmaceutical products”. NPIL’s R&D focus is designed  
to maximise opportunities throughout the research value chain. Its R&D programme  
is divided into four strategic business units, each focusing on different aspects of and 
opportunities in pharmaceutical research: basic research – on new drug discovery; natural 
products; clinical research – on providing quality clinical and bio-analytical support to 
facilitate the international introduction of generic products to support research on NDDS 
and clinical development of new chemical entities; and genomics research – translating 
cutting-edge research into innovative applications. R&D investment is quite low 
compared to other domestic pharmaceutical firms, at 2% of sales. However, recognising 
the importance of basic research in this knowledge-based industry, NPIL has made 
strategic investments in its research centres.  
NCE research is currently concentrating on three lead molecules in the diabetes, 
oncology and anti-infective fields. All three molecules are in the preclinical stage. 
According to Dr. Sikka, “the goal of the NDDS division is to develop novel formulations 
of already approved drugs and gradually develop an innovative technology platform”. 
Capex, a new R&D facility, is being created at Goregaon, Mumbai, to house the 
expanded R&D team. This new facility will be utilised to pursue rheumatology and 
cancer research, in addition to the ongoing diabetes and anti-infectives projects, as  
Dr. Sikka informed the researcher during the interview. The research strategy in NPIL 
appears to be driven by ‘research services’. Accordingly, NPIL is creating infrastructure 
and investing on skills development for clinical research and contract manufacturing. 
4.5 Sun Pharmaceuticals Limited 
Following the same path as NPIL, growth through mergers and acquisitions,  
Sun Pharmaceuticals has taken major strides quickly. Sun manufactures and markets 
specialty medicines and APIs for chronic therapy areas such as cardiology, psychiatry, 
neurology and gastroenterology. According to one of its senior managers, Sun was one of 
the earliest among Indian companies to invest in research. Serious resources were 
committed to research in 1993 when it was a much smaller company. Ever since, 4% of 
an increasing turnover has been invested every year on time-bound projects at the 
company’s research centre, Sun Pharma Advanced Research Centre (SPARC).  
SPARC works on process synthesis, dosage forms, NCEs and NDDS. The research 
strategy has been phased in three stages. In the first phase, which has been accomplished, 
the emphasis was on reverse engineering and on high-yield processes for specialty  
bulk drugs. The processes developed for specialty bulk actives at SPARC enabled  
the company to commercialise more than 60 specialty bulk actives in just seven years 
(1993–2000), several of which are based on novel and non-infringing processes. In the 
second phase, the focus is on innovative drug delivery systems and alternative patentable 
routes. The output of the first and second phase coupled with increasing investments in 
the infrastructure and resources (financial as well as technical) equips the company for 
drug design in the long term, which is the third phase.  
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Based upon my discussions with managers, Sun Pharma’s research approach  
appears to be incremental: from simpler dosage forms to NDSS and complex bulk 
actives. The research focuses on new chemical entities and NDSS. From about 30% of 
the current research budget allocated to innovation-based projects, the company expects 
to increase it to 70% over the next three years (interview). 
4.6 Lupin India Limited  
Lupin, a global leader in the anti-TB segment, is the world’s largest manufacturer of 
Ethambutol and Rifampicin (through the complex fermentation process). Its Rifampicin 
plant is one of only three plants in the world approved by the US Food and Drug 
Administration (USFDA). Most of its products are placed in the top three positions  
under different categories of anti-TB segments (OPPI, 2003). Being the world’s  
largest integrated manufacturer of cephalosporins, Lupin has a strong presence in  
this segment. Other principal therapeutic areas are cardiovasculars and Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs). According to Dr. Sen, President of R&D and 
Regulatory Affairs: 
“Lupin spends more than 5% of its sales on research activities. The company’s 
R&D Park in Pune city near Mumbai, conducts leading-edge research in 
generics, new chemical entities (NCEs), Novel Drug Delivery Systems 
(NDDS), Oral Controlled Release Systems (OCRS) and phytomedicines.” 
The company has devised twin strategies for the short and long term. The short-term 
goals are driven by market rather than research. Building upon its existing R&D 
competencies in the anti-TB sector, Lupin is augmenting its product portfolio and 
broadening its market and distribution network. The strategy is to identify and implement 
profitable operations without new drug discovery in the short term. The short-term 
strategy is devised on the market opportunities that exist today and Lupin’s core 
competencies in exploiting them. To fully utilise its backward integration expertise, 
Lupin has entered into the business of fixed dosage formulations and is exploiting 
synergy by entering those therapeutic formulations which require APIs where Lupin is 
already present, like cephalosporins and ACE inhibitors. 
The long-term research focus is on developing NDDS, herbal products and NCEs. 
Herbal research is accorded a high priority. Realising the fact that formulation business 
for conventional-TB disease in the near future is not promising (as most of the demand 
comes from Third-World countries, low profit margins and strong national health 
services), Lupin appears to be steering a shift in its product mix in the coming years. 
4.7 Cadila Pharmaceuticals Limited (CPL) 
Positioned as a research-based, technology savvy firm, Cadila Pharmaceuticals Limited 
(CPL) has current focus on areas like branded formulations (human and veterinary), 
NCEs, NDDS, APIs, bulk drugs, vaccines and immunoglobulins (Company Interviews 
and Annual Reports, 2000–2004). Ongoing investment is made for basic and applied 
research in phytochemistry, biotechnology, plant tissue culture, toxicology, analytical 
research and genetic engineering (interview). There are three separate research units, 
namely Chemical, Biotechnology and Generics.  
Cadila Pharmaceuticals is revitalising its research and business through a  
mix of conventional and modern approaches. According to Dr. P.K. Ghosh,  
Head – Biotechnology: 
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“Innovation in products and processes may be achieved by the firms faster 
based on a systematic technology breakdown and mapping of each 
technological trajectory with possible application areas, already experimented 
and exploited in the research institutions rather than reinventing the wheel  
in-house. The collaboration and cooperation method enables one to direct joint 
efforts on the most prominent research topics.” 
Based on this philosophy, the firm has established a strong R&D base in biotechnology 
and developed working relations with key R&D institutes in the country for outsourcing 
of research and development. Interactions with Cadila suggest that as of today, Cadila 
does not invest much in basic R&D and does only developmental work. The company 
rather buys or collaborates with research institutes and picks up lab-proven technologies 
to upgrade and commercialise. Through collaborations and networking CPL intends to 
source complementary assets and expertise from external sources while simultaneously 
building their in-house capabilities to assimilate, absorb and innovate upon.  
Cadila’s current R&D strategy is to transform itself from a chemical formulation 
outfit to a true life sciences company. However, the expertise and core technological 
strengths developed over the years in chemical formulations are being exploited by 
implementing innovative manufacturing and marketing strategies. Thus, on one hand  
the company has captured the high-volume market by developing generics and on  
the other the company is investing seriously in life sciences in order to capitalise on the 
future opportunities.  
5 Key observations and analysis 
5.1 Enhanced R&D investments 
Under the process patent regime, Indian firms effectively used reverse engineering to 
make patented products and emerged as major generic manufacturers. Competitive 
pressures induced through liberalisation in 1991 constrained the benefits from imitation 
and hence restricted its use. Later, changes in patent law under the TRIPs obligation, 
preventing the reverse engineering of patented molecules, forced Indian firms to enhance 
their R&D efforts and investments. The total R&D expenditure, which was only Rs. 3 
crores in 1965–1966, reached an impressive Rs. 140 crores in 1995, a significant  
year, when the WTO and IPR protection came into being. With the increasing realisation 
that copying will no longer be permissible after 2005, R&D investments have gained 
serious momentum since 2000. From a paltry sum of Rs. 140 crores in 1995, it went up to 
Rs. 200 crores in 2002 and was expected to exceed Rs. 1000 crores in 2004 (IDMA, 
various bulletins).  
Firms have cited different reasons for low R&D investment. According to some, the 
process patent regime coupled with a protected market prevented Indian firms from 
investing more on R&D. My analysis of firms’ views suggests that initially there was a 
large, ready domestic market for cheap generic drugs available to Indian firms. As the 
domestic market became saturated, other developing countries and Russia served as  
the primary markets for finished formulations. Thus neither market-pull nor policy-push 
was there to encourage research and innovation. Consequently, research was limited to 
better production processes which required minimal research and hence low investment.  
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Lately, with the change in patent laws and policy scenario, large pharmaceutical  
firms have begun to invest in R&D. The case studies suggest that from about 2% of  
total sales around three to four years ago, the average R&D expenditures of the leading  
research-based domestic firms has gone up to around 5%–6% in 2003–2004 (Table 3). 
Among these companies Ranbaxy, Dr. Reddy’s, Cipla, Wockhardt, Torrent, Sun, Lupin, 
NPIL and Aurbindo are prominent. Dr. Reddy’s R&D expenditure increased from 7% in 
2002–2003 to 10% in 2003–2004 and is slated to increase further in future. 
Table 3 R&D investments in selected Indian pharmaceutical firms 
R&D spending as percentage of sales 
Company 1999–2000 2000–2001 2001–2002 2002–2003 2003–2004 2004–2005* 
Ranbaxy 3.6 4.2 4.0 5.0–5.5 6.3 7.0–8.0 
Dr. Reddy’s 2.7 3.5 4.0–4.5 6.8 9.9 12.9 
Cipla 3.5 3.5 4.0–4.5 4.5–4.8 4.8–5.0 5.0–5.5 
NPIL 2.0 2.0 2.0 2.0 4.0 5.0 
Sun 4.0 4.0 4.0 7.0 10.0 10.0–12.0 
Lupin 1.7 2.0 2.0 3.0 3.0–3.5 8.0 
Dabur – – – – 8.0–9.0 8.0–9.0 
Cadila Pharma 1.0–2.0 1.0–2.0 1.0–2.0 2.0 2.0–3.0 3.0–4.0 
Note: * represents projected investments 
Source: Compiled by the author from various sources (company interviews, 
annual reports, journal articles and press releases) 
NPIL has doubled its R&D spending from 2% (in 2002–2003) to 4% (in 2003–2004).  
Torrent Pharma’s R&D expenditure increased from around 5% (in 2001–2002) to 9%  
(in 2003–2004) and is expected to go to 10%–11% (in 2004–2005). 
5.2 Enhanced patent filings 
The number of patents filed and granted in a particular sector indicates the level of 
inventive activity and R&D capabilities of a country in that sector. Two Indian entities, 
Council of Scientific and Industrial Research (CSIR) and Ranbaxy, find mention in  
the 2002 top ten list of the World Intellectual Property Organization (WIPO). Patent 
applications by industry during 1995–2000 indicate that pharmaceuticals rank highest 
with 396 applications (Journal of Intellectual Property Rights, various issues). 
Indian firms have been filing Abbreviated New Drug Applications (ANDAs) and 
Drug Master Files (DMFs) internationally primarily to gain entry into regulated markets. 
India filed more than 112 ANDAs in 2003 and 392 in 2002. India’s share of ANDA 
filings has been rising consistently and was around 23% in 2003. Indian firms accounted 
for over 30% of the DMFs filed in the USA in 2003. It remained in first position with  
126 DMFs in 2003 alone (India Folio, 2004). This indicates not only the present level  
of patenting activity in Indian pharmas but commitment (pipeline) for the future as  
well. Firms have realised the need for beginning serious R&D for new drugs and 
patenting them. Top companies such as Ranbaxy, Dr. Reddy’s, Sun, Cipla, Lupin and 
many others have enhanced their patent filings. Table 4 briefly summarises patenting 
activity in Indian firms. 
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Table 4 Patents filings by Indian pharmaceutical firms 
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Firms have used multiple approaches to create intellectual property, such as filing for 
Indian patents, international patents, ANDAs and DMFs. Firms like Dr. Reddy’s and 
Ranbaxy have made use of first-to-file and Para IV filings as well. However, other firms 
like Cipla, Cadila, Lupin, Sun and Zydus have opted for DMFs to gain cheaper and faster 
entry to regulated markets. The increase in the number of patent filings in the recent past 
and ambitious targets set up for the future strongly suggest that TRIPs has stimulated 
both R&D activity and filing of patents in the Indian pharmaceutical industry. 
5.3 Enhanced research, licensing and outsourcing partnerships 
Partnerships, collaborations and alliances have become increasingly common in the 
pharmaceutical industry not only in India but worldwide. Discussions with Indian firms 
suggested strongly that partnerships have become the most important and integral part of 
the overall corporate strategy since the mid-1990s. Indian firms have collaborated with 
premium technology and research institutions to change their market image (research 
driven); have acquired and merged to elevate their market position (size, brands) or to 
have access to certain technologies or markets; and have formed alliances to shift their 
market focus (from developing to developed); or have moved up the higher value chain 
by acquiring or collaborating for gaining new knowledge and skills from external 
sources. Ranbaxy, Cipla, Lupin, Cadila Pharmaceuticals, Dabur, Zydus, Wockhardt, Sun 
and Torrent are all involved in such alliances.  
Various forms of strategic partnerships such as collaborative research, contract 
research, co-production agreements, co-marketing arrangements, cross-distribution 
arrangements, technology licensing and Mergers and Acquisitions (M&As) are 
increasingly being utilised for capacity additions, brand acquisitions, marketing channel 
integration, and R&D integration, depending upon the focus of a firm. Ranbaxy, Sun and 
DRL have acquired assets or formed alliances with the firms based in other countries to 
expand their international presence, on one hand, and have collaborated with other firms 
and premium technology institutes to strengthen their technology base. Sun Pharma’s 
acquisition of Knoll’s bulk laboratory, for instance, was motivated by the firm’s 
technological strengthening strategy. Similarly repeated M&As with the leaders have 
provided NPIL with competitive edge over other firms in terms of innovative product line 
and a well-defined marketing and distribution network. Acquiring firms with existing 
innovative product lines or products in the advanced stage of development appears to be a 
feasible and favourable option for Indian firms. In addition, Indian firms have also 
acquired generic drug companies abroad or even set up manufacturing joint ventures in 
order to seize the international generics opportunity. For instance, Ranbaxy has expanded 
its presence internationally by acquiring Rima Pharmaceuticals in Ireland and Ohm 
Laboratories in the USA. Dr. Reddy’s has an agreement with Pharmaceutical Resources 
Inc., USA to supply bulk drugs and intermediates.  
These trends suggest that M&As are likely to be a continuing feature in the 
pharmaceutical landscape as firms seek to grow and consolidate market positions while 
still capitalising on new research opportunities. There is an increasing recognition in 
Indian pharmaceutical firms that one company’s peripheral technologies are another’s 
core activities, and that it makes sense to source such technologies externally rather  
than to incur the risks, costs and most importantly of all, time scale associated with the  
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in-house development, especially in NDD. Coordinating and redeploying internal and 
external sources appears to be the key strategy adopted by the firm to address the rapidly 
changing technology and business environments.  
Subcontracting of research is a recent phenomenon in the pharmaceutical industry. 
Earlier, subcontracting in pharmaceuticals was mainly restricted to intermediate or API 
suppliers. Now, as the firms are moving up the higher value chain and competing to 
launch new drugs, subcontracting for research, advanced clinical trials, custom synthesis, 
marketing and sales support are gaining popularity. Indian firms (Ranbaxy, Cipla,  
Dr. Reddy’s, NPIL) realise that it will be difficult for them to commercialise their 
discoveries on an international basis on their own and hence they are getting into 
licensing deals and strategic alliances with international companies. The cases under 
study suggest a change in the traditional technology development and commercialisation 
practices (where most of the innovations have emerged from in-house R&D efforts) to 
more open and participative approaches. 
5.4 New motives: strategic integration of knowledge and technology 
The literature review, together with case studies in this paper, suggests that the focus  
of collaborations in 1990s was on integrating brands, manufacturing capacities, and 
marketing and distribution networks. Vertical integration achieved new heights during 
this period. Ranbaxy, NPIL, Sun, Lupin and Cipla all expanded their manufacturing 
operations, marketing and distribution networks, product portfolios and brands through 
backward and forward integration. Ranbaxy bought a 30% stake in Vorin Laboratories in 
order to gain control over a key raw material and an intermediate supplier for its famous 
product Ciprofloxacin. This backward integration gave many benefits to the company. 
Sun Pharma has also utilised acquisitions for its organic and inorganic growth. Its 
acquisition of MJ Pharma and Gujarat Lyka was a part of its multimedia strategy, while 
integrating TDPL is an entry strategy into specialty areas like oncology, gynaecology and 
pain management.  
Brand acquisition in India was initiated by Dr. Reddy’s, who acquired Riflux and 
Clamp from Sol Pharma to supplement its existing anti-ulcer products range. The  
trend was feverishly followed by other firms. Ranbaxy acquired Mox, a top brand  
of the Amoxycillin drug, in addition to integrating an entire range of antibiotics  
and dermatological brands of Gufic Laboratories. The Piramal Group acquired 
Analgin/Aspirin fame from Nicholas. Later it took over Roche products like Valium to 
add to its product basket. These collaborations were particularly driven by market 
liberalisation in the 1990s.  
However, with the signing of TRIPs in 1995 and changes in the patent laws, the focus 
of collaborations has shifted to R&D. The emphasis is on knowledge and technology 
integration rather than the critical mass and economies of scale. Many top Indian firms 
have pursued collaborations with international drug companies to access technology and 
knowledge vigorously in the last five years or so, for example, Ranbaxy with Eli Lilly 
and Gist Brocades, Dr. Reddy’s with Novartis and Novo Nordisk, Lupin with Merck 
Generics and Wyeth Lederle, Torrent Pharmaceuticals with Novo Nordisk of Denmark 
and Sanofi of France and Cadila Pharmaceuticals with M.M. Schwabe, USA. These 
trends suggest a change in the mindset of Indian entrepreneurs and a change in the 
motives behind strategic alliances pursued by the Indian firms. 
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NPIL has identified leaders to partner with in order to gain technology, knowledge 
and expertise in its area of choice. The combined scientific teams of Hoechst R&D 
Centre, acquired recently by NPIL, and its earlier acquisitions of Boehringer Mannheim 
and Roche, provide it with an instant and unmatched knowledge base (more than DRL  
and Ranbaxy). Sun Pharma is another exemplary case of gaining access to technology 
and knowledge through acquisition strategy. Its acquisition of USFDA-approved Caraco 
Pharma Labs and UKMCA-approved MJ Pharmaceuticals provided Sun with a quick 
access to the proprietary knowledge created by these firms.  
Accessing new knowledge from external sources has become extremely strategic in 
nature in the recent past. The straightforward sale and purchase of contemporary 
technologies is no longer a feasible option. Therefore, new modes are constantly 
emerging to acquire and access knowledge from external sources and internalise it. 
Acquiring or collaborating with firms with existing knowledge base, innovative product 
lines or products in the advanced stage of development appears to be a feasible and 
favourable option for Indian firms. Table 5 summarises the knowledge diffusion level 
associated with different kinds of collaborations and the use of these mechanisms in 
Indian firms. 
Table 5 Forms of collaboration and knowledge diffusion 
Type of 
collaboration 
Typical 
duration 
Advantages 
(rationale) 
Disadvantages 
(transaction costs) 
Examples of 
Indian firms Diffusion 
Subcontract Short term Cost and risk 
reduction, reduced 
lead time 
Search costs, product 
performance and 
quality 
Ranbaxy, DRL, 
NPIL 
Low 
Cross-licensing Fixed term Technology 
acquisition 
Contract cost and 
constraints 
Cipla, NPIL High 
Consortia Medium 
term 
Expertise, standards, 
share funding 
Knowledge leakage 
and subsequent 
differentiation 
Dabur, Cadila, 
HAL 
High 
Strategic alliance Flexible Low commitment, 
market access 
Potential lock-in 
and knowledge 
leakage 
Zydus, Sun, 
Lupin, Ranbaxy 
Medium 
Joint venture Long term Complementary 
know-how, dedicated 
management 
Strategic drift and 
cultural mismatch 
NPIL, Ranbaxy, 
Cadila 
Medium 
Network Long term Dynamic, learning 
potential 
Static inefficiencies Ranbaxy, DRL, 
Dabur, Cadila 
High 
Source: Fieldwork data from India 
5.5 India’s capability creation and value chain progression 
Previously, Indian firms began reverse engineering somewhere from the middle of the 
chain, that is, the process development, totally omitting the discovery and basic research 
part. Through backward and forward integration the firms advanced gradually from the 
stage of duplicate imitation to the creative imitation stage, that is, the generics and chiral 
synthesis. Though most of the medium- and small-scale firms got locked here, larger 
firms moved to the next stage of development, that is, the NDDS. Most of the companies 
are now involved in analogue research, which is one step behind the NCE research 
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(Figure 1). Moving up the value chain, firms have created core competencies in the 
middle part of the chain. The level of expertise achieved is so high that most of the firms 
appear to be well prepared for providing services to multinationals, and in turn the 
missing links in the drug discovery and innovation chain are strategically organised from 
external sources for in-house research. This indicates that Indian firms have indeed 
progressed and upgraded their status from mere ‘followers to partners’. 
Figure 1 Progressive drug discovery paradigm of Indian firms 
Collective analysis of selected cases implies that firms are adapting to the changing 
environments by making midway strategic corrections and are continuously integrating 
new parallel streams in the mainstream of corporate strategy. R&D is recognised as  
the ‘survival kit’ in the post-2005 scenario and building the science base for innovations 
is deemed necessary for long-term growth by Indian leaders. However, firms do 
recognise the risk involved in discovering and competing in open markets on the basis of 
drug discovery (path) alone. Hence, contingency plans are being made along with 
developing drug discovery capabilities. Most firms have reconfigured their research on 
short-, medium- and long-term bases. Firms have strategised to maintain a steady cash 
flow, tapping the large US generics market in the short term. In the medium term, they 
intend to move up the value chain through NDDS, which can be patented, and finally in 
the long term to launch their own molecules. 
6 Conclusion 
Combining ‘drug discovery and generics strategies’ is the model practised by the Indian 
firms. However, as an evolutionary perspective would suggest, each firm has its own 
distinctive approach. The accumulation of skills, technical know-how and expertise, 
whether at the level of firms or countries, takes time and is a process pertinent to long-run 
economic development. Our case studies in this paper suggest that technology and 
innovation is not something which firms buy-in from outside. On the contrary, it is rooted 
in a specific set of change-generating resources (context) or absorptive and innovative 
Paradigms                             Shifts
 
 
 
Knowledge Base 
 
 
Research 
Drug Development 
 
Time scale 
Minimal Information     Increasing Knowledge         3D-Information          
Minimum Knowledge (Explicit)             Complex Knowledge (Tacit)        
Duplicative Imitation                       Creative Imitation              Incremental Innovation                      New Innovation Research 
R&D = Reverse Engg                     R&D = Generics,               R&D = NDDS and                               New Chemical Entities   
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capability firmly rooted within the structure of technology-oriented firms. The particular 
profile of each firm’s approach needs to be understood in light of its own history. Each 
firm under investigation in this research has a rich mix of resources and has accordingly 
chalked out a strategy for itself. Although there are many commonalities, there are quite  
a few differences in approach and implementation of broad strategies. Ranbaxy’s  
combo-strategy is to plough back profits from its generics business in the USA into new 
drug research in India. In research, also, Ranbaxy has alleviated its risk by focusing on 
NDDS instead of a sole thrust on NCEs. Although DRL has its major focus on NCEs, the 
firm is integrating NDDS and generics in its overall business strategy. Firms like Cipla, 
NPIL and Sun are intensifying their research and market activities but on new improved 
and value-added products rather than new drugs, based on their capabilities and expertise 
created in the past. Other firms that have now combined their traditional strategies with 
research are Dabur, Lupin, Wockhardt, Torrent, Cadila Alembic, and NPIL. 
Firms are formulating future research and business strategies in different 
combinations and permutations of NCEs, NDDS, generics, contract manufacturing, 
conducting of clinical trials, and in-and out-licensing agreements. Aligning  
‘service-based business strategies’ alongside the ‘drug discovery’, which are being 
vigorously pursued by the top-level firms is basically a strategic combination of imitative 
and innovative capabilities. Ranbaxy, DRL and Cipla are judiciously exploiting  
combo-strategies to combat the competitive pressures faced by the generic industry as 
well as to capture research-based high-end markets. Although the outcome of these 
contemporary strategies is yet to be seen, they provide a road map worth considering to 
new entrants. 
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